An interventional study of PPC and Usual care in Dementia, sponsored by The University of Texas Health Science Center, Houston. Completed at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.
Among the 1,051 studies in Dementia with a site in United States, this one is the 410th largest by enrollment of the 846 interventional ones that give a count, is one of 87 that started in 2023, is one of 562 with no phase, and was the 821st registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 50+ · Women only · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 50–100 · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 21+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,051 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 73 · Phase 2 146 · Phase 3 79 · Phase 4 33
First in 1981; this study’s year is marked. 87 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is close to the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 93 across the 846 interventional studies, 200 across the 200 observational. Of the 715 that completed or were terminated, 309 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
191 of 1,051 have an industry lead sponsor. The 10 most frequent:
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
The University of Texas Health Science Center, Houston has 3 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
107 of the studies in Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT07430371Rendever, Inc.Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES) | 2026-11 |
| NCT06095284Virginia Commonwealth UniversityPrescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic | 2026-11-30 |
| NCT06298474Hopeful AgingThe BRAIN App (Phase 2 SBIR) | 2026-11-30 |
| NCT07859865Drexel UniversityMindfulness-based Movement Therapy for Persons With Dementia and Family Caregivers | 2026-11-30 |
Add all 107 to your calendar (.ics) → With an account.
Among the 1,051 studies in Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare patient priorities care (PPC) and usual care (UC) patients to identify differences in post-encounter medication changes, treatment burden (TBQ), and shared decision making in Older Patient Assessment of Chronic Illness Care (OPACIC), to understand PPC participant's sense-making and communication approaches related to deprescribing decisions in relation to the identified health priorities and to identify and categorize adverse drug withdrawal events (ADWEs)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: PPC
Behavioral: Usual care
Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.
Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.
Total Number of Medication Changes
Total Number of medication changes that happened between baseline and three month follow up among Dementia Participants.
Time frame: Baseline, 3 month
Type of Medication Changes
Medication changes corresponding to the type of changes among Dementia Participants: added or increased, discontinued or decreased, avoided.
Time frame: Baseline, 3 month
Number of Participants by Change in Patient Report Treatment Burden as Assessed by the Treatment Burden Questionnaire (TBQ)
The questionnaire consists of 15 items, each scored on a scale from 0 (not a problem) to 10 (a very big problem), yielding a total score range of 0 to 150, with higher scores indicating greater treatment burden. TBQ total scores were assessed at baseline and at 3 months. Change in treatment burden was calculated by subtracting the baseline total TBQ score from the 3-month TBQ score (3 month minus baseline). Participants were categorized based on change in score as follows: * reduced burden (change score \< 0) * no change in burden (change score = 0) * increased burden (change score \> 0)
Time frame: Baseline, 3 month
Number of Participants by Likelihood of Adverse Drug Reactions (ADRs) as Assessed by the Naranjo Scale
Naranjo scale is a questionnaire used to assess the likelihood that an adverse event is related to a drug. Total scores range from -4 to +13. Adverse drug reactions were categorized based on total score as follows: * Definite (≥ 9): Reaction followed a reasonable temporal sequence after drug exposure, matched a recognized drug response, improved after withdrawal, and recurred upon re-exposure. * Probable (5 to 8): Reaction followed drug exposure, matched a recognized drug response, improved after withdrawal, and was not reasonably explained by the patient's clinical condition. * Possible (1 to 4): Reaction followed drug exposure and may fit a recognized drug response but could also be explained by the underlying disease or other factors. * Doubtful (≤ 0): The reaction was due to factors other than a drug. * No Adverse Reaction: Participants who did not experience any adverse reactions. The Naranjo Scale was not administered because there was no suspected reaction to evaluate.
Time frame: 3 months
Number of Participants by Adverse Drug Withdrawal Events (ADWEs) as Assessed by the Naranjo Scale
The Naranjo Scale assesses the likelihood that an adverse event is related to a drug withdrawal. Total scores range from -4 to +13. Adverse drug withdrawal events (ADWEs) were categorized as follows: * Definite (≥ 9): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with treatment or re-exposure, and recurred after subsequent discontinuation * Probable (5 to 8): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with management or re-exposure, and could not be explained by the patient's condition * Possible (1 to 4): Withdrawal reaction followed drug discontinuation and may fit a recognized withdrawal syndrome but could also be explained by an underlying disease or other factors. * Doubtful (≤ 0): Withdrawal reaction likely due to factors other than drug discontinuation * No Withdrawal Reaction: No suspected adverse drug withdrawal event. The Naranjo Scale was not administered
Time frame: 3 months
Change in Patient Perceived Chronic Disease Care as Assessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) Score
The Older Patient Assessment of Chronic Illness Care (OPACIC) score ranges from 10 to 50, with higher scores indicating better perceived chronic disease care. The change in score is reported as \[(OPACIC score at 3 months) - (OPACIC score at baseline)\]--a positive value indicates improvement in perceived chronic disease care over time.
Time frame: Baseline, 3 months
| Milestone | Patient Priorities Care: Intervention Group | Usual Care: Control Group |
|---|---|---|
| Started | 68 | 30 |
| Completed | 64 | 30 |
| Not completed | 4 | 0 |
Total Number of medication changes that happened between baseline and three month follow up among Dementia Participants.
| Number of Medication Changes | Patient Priorities Care: Intervention Group | Usual Care: Control Group |
|---|---|---|
| Total Number of Medication Changes | 24 | 14 |
Medication changes corresponding to the type of changes among Dementia Participants: added or increased, discontinued or decreased, avoided.
| Number of Medication changes | Patient Priorities Care: Intervention Group | Usual Care: Control Group |
|---|---|---|
| Medications added or increased | 16 | 7 |
| Medications avoided | 2 | 5 |
| Medications discontinued or decreased | 6 | 2 |
The questionnaire consists of 15 items, each scored on a scale from 0 (not a problem) to 10 (a very big problem), yielding a total score range of 0 to 150, with higher scores indicating greater treatment burden. TBQ total scores were assessed at baseline and at 3 months. Change in treatment burden was calculated by subtracting the baseline total TBQ score from the 3-month TBQ score (3 month minus baseline). Participants were categorized based on change in score as follows: * reduced burden (change score \< 0) * no change in burden (change score = 0) * increased burden (change score \> 0)
| Participants | Patient Priorities Care: Intervention Group | Usual Care: Control Group |
|---|---|---|
| Reduced burden (change score < 0) | 6 | 7 |
| No change in burden (change score = 0) | 0 | 1 |
| Increased burden (change score > 0). | 16 | 1 |
Naranjo scale is a questionnaire used to assess the likelihood that an adverse event is related to a drug. Total scores range from -4 to +13. Adverse drug reactions were categorized based on total score as follows: * Definite (≥ 9): Reaction followed a reasonable temporal sequence after drug exposure, matched a recognized drug response, improved after withdrawal, and recurred upon re-exposure. * Probable (5 to 8): Reaction followed drug exposure, matched a recognized drug response, improved after withdrawal, and was not reasonably explained by the patient's clinical condition. * Possible (1 to 4): Reaction followed drug exposure and may fit a recognized drug response but could also be explained by the underlying disease or other factors. * Doubtful (≤ 0): The reaction was due to factors other than a drug. * No Adverse Reaction: Participants who did not experience any adverse reactions. The Naranjo Scale was not administered because there was no suspected reaction to evaluate.
| Participants | Patient Priorities Care: Intervention Group |
|---|---|
| Definite (Score is 9 or higher) | 0 |
| Probable (Score is 5 to 8) | 0 |
| Possible (Score is 1 to 4) | 3 |
| Doubtful (-4 to 0) | 0 |
| No Adverse Reaction | 27 |
The Naranjo Scale assesses the likelihood that an adverse event is related to a drug withdrawal. Total scores range from -4 to +13. Adverse drug withdrawal events (ADWEs) were categorized as follows: * Definite (≥ 9): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with treatment or re-exposure, and recurred after subsequent discontinuation * Probable (5 to 8): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with management or re-exposure, and could not be explained by the patient's condition * Possible (1 to 4): Withdrawal reaction followed drug discontinuation and may fit a recognized withdrawal syndrome but could also be explained by an underlying disease or other factors. * Doubtful (≤ 0): Withdrawal reaction likely due to factors other than drug discontinuation * No Withdrawal Reaction: No suspected adverse drug withdrawal event. The Naranjo Scale was not administered
| Participants | Patient Priorities Care: Intervention Group |
|---|---|
| Definite (Score is 9 or higher) | 0 |
| Probable (Score is 5 to 8) | 0 |
| Possible (Score is 1 to 4) | 0 |
| Doubtful (Score is -4 to 0) | 0 |
| No withdrawal reaction | 30 |
The Older Patient Assessment of Chronic Illness Care (OPACIC) score ranges from 10 to 50, with higher scores indicating better perceived chronic disease care. The change in score is reported as \[(OPACIC score at 3 months) - (OPACIC score at baseline)\]--a positive value indicates improvement in perceived chronic disease care over time.
| score on a scale | Patient Priorities Care: Intervention Group | Usual Care: Control Group |
|---|---|---|
| Change in Patient Perceived Chronic Disease Care as Assessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) Score | 1.72 ± 8.7 | 0.5 ± 14.05 |
Collected over Up to 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patient Priorities Care: Intervention Group | 0/34 (0%) | 0/34 (0%) | 3/34 (8.8%) |
| Usual Care : Control Group | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Event | Patient Priorities Care: Intervention Group | Usual Care : Control Group |
|---|---|---|
| Sleep disorderGeneral disorders | 1/34 | 0/15 |
| Urinary IncontinenceRenal and urinary disorders | 1/34 | 0/15 |
| Edema in legsGeneral disorders | 1/34 | 0/15 |
Baseline characteristics data includes all participants who completed the study
| Age, Continuous(Years) | Patient Priorities Care: Intervention Group | Usual Care : Control Group | Total |
|---|---|---|---|
| Dementia Participant | 84.39 ± 7.80 | 82.13 ± 6.59 | 83.38 ± 7.21 |
| Caregiver | 61.13 ± 11.58 | 65.00 ± 11.42 | 62.27 ± 11.54 |
| Sex/Gender, Customized(Participants) | Patient Priorities Care: Intervention Group | Usual Care : Control Group | Total |
|---|---|---|---|
| Dementia Participant — Female | 22 | 11 | 33 |
| Dementia Participant — Male | 10 | 4 | 14 |
| Dementia Participant — Not Reported | 0 | 0 | 0 |
| Caregiver — Female | 26 | 9 | 35 |
| Caregiver — Male | 5 | 6 | 11 |
| Caregiver — Not Reported | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Patient Priorities Care: Intervention Group | Usual Care : Control Group | Total |
|---|---|---|---|
| Dementia Participant — Hispanic or Latino | 4 | 2 | 6 |
| Dementia Participant — Not Hispanic or Latino | 28 | 13 | 41 |
| Dementia Participant — Unknown or Not Reported | 0 | 0 | 0 |
| Caregiver — Hispanic or Latino | 4 | 2 | 6 |
| Caregiver — Not Hispanic or Latino | 26 | 12 | 38 |
| Caregiver — Unknown or Not Reported | 2 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Patient Priorities Care: Intervention Group | Usual Care : Control Group | Total |
|---|---|---|---|
| Dementia Participant — White | 16 | 8 | 24 |
| Dementia Participant — Black or African American | 12 | 5 | 17 |
| Dementia Participant — Other | 3 | 2 | 5 |
| Dementia Participant — Not reported | 1 | 0 | 1 |
| Dementia Participant — More than One Race | 0 | 0 | 0 |
| Dementia Participant — American Indian or Alaska Native | 0 | 0 | 0 |
| Dementia Participant — Asian | 0 | 0 | 0 |
| Dementia Participant — Native Hawaiian or Other Pacific Islande | 0 | 0 | 0 |
| Caregiver — White | 16 | 8 | 24 |
| Caregiver — Black or African American | 10 | 4 | 14 |
| Caregiver — Other | 4 | 0 | 4 |
| Caregiver — Not reported | 2 | 2 | 4 |
| Caregiver — More than One Race | 0 | 1 | 1 |
| Caregiver — American Indian or Alaska Native | 0 | 0 | 0 |
| Caregiver — Asian | 0 | 0 | 0 |
| Caregiver — Native Hawaiian or Other Pacific Islande | 0 | 0 | 0 |
| Region of Enrollment(participants) | Patient Priorities Care: Intervention Group | Usual Care : Control Group | Total |
|---|---|---|---|
| United States | 64 | 30 | 94 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Jun 2025, 23 months.
Results were first posted in Nov 2026, 1 year 4 months after primary completion.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 23 months is close to that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center, Houston →